Metastasis induced by overexpression of p185(neu-T) after orthotopic injection into a prostatic epithelial cell line (NbE)

Molecular Carcinogenesis

Volumn 19, Issue 3, 1997, Pages 165-175

  Marengo, Susan Ruth ^a   Sikes, Robert A ^a,b   Anezinis, Ploutarchos ^a   Chang, Shi Ming ^a,b   Chung, Leland W K ^a,c  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^c UNIVERSITY HOSPITAL OF IRAKLION   (Greece)

Author keywords

erB 2; P185(neu T) metastasis; Prostate

Indexed keywords

ONCOPROTEIN; PROTEIN P185; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL ISOLATION; CONTROLLED STUDY; EPITHELIUM CELL; GENE ACTIVATION; HISTOPATHOLOGY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE EPITHELIUM; TUMOR GROWTH;

ADENOCARCINOMA; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; EPITHELIUM; MALE; MICE; MICE, NUDE; MUSCLE NEOPLASMS; MUSCLE, SKELETAL; MUTATION; NEOPLASM TRANSPLANTATION; PHENOTYPE; PROSTATE; PROSTATIC NEOPLASMS; RATS; RATS, INBRED STRAINS; RECEPTOR, ERBB-2; TRANSFECTION; TUMOR CELLS, CULTURED;

ANIMALIA; MUS MUSCULUS;

EID: 0030749568     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2744(199707)19:3<165::AID-MC4>3.0.CO;2-D     Document Type: Article

References (50)

1. Dougall WC, Qian X, Peterson NC, Miller MJ, Samanta A, Greene MI. The neu-oncogene: Signal transduction pathways, transformation mechanisms and evolving therapies. Oncogene 9:2109-2123, 1994.
2. Zhau HE, Sikes RA, Chung LWK. The c-erbB-2 oncogene in human prostate cancer growth and progression. In: Khan SA, Stancel GM (eds), Protooncogenes and Growth Factors in Steroid Hormone Induced Growth and Differentiation, Vol 12. CRC Press, Ann Arbor, 1994, pp. 207-220.
3. Ben-Baruch N, Yarden Y. Neu differentiation factors: A family of alternatively spliced neuronal and mesenchymal factors. Proc Soc Exp Biol Med 206:221-227, 1994.
4. Carraway KL III, Cantley LC. A neu acquaintance for ErbB3 and ErbB4: A role for receptor heterodimerization in growth signaling. Cell 78:5-8, 1994.
5. erbB2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. J Natl Cancer Inst 86:1140-1145, 1992.
6. Wainstein MA, He R, Robinson D, et al. CWR22: Androgen-dependent xenograph model derived from a primary human prostatic carcinoma. Cancer Res 54:6049-6052, 1994.
7. Peles E, Bacus SS, Raymond AK, et al. Isolation of the neu/HER-2 stimulatory ligand: A 44 kD glycoprotein that induces differentiation of mammary tumor cells. Cell 69:205-216, 1992.
8. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Mueller WJ. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA 89:10578-10582, 1992.
9. Di Fiore PP, Pierce JH, Kraus MH, Segatto O, King CR, Aaronson SA. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 237:178-182, 1987.
10. Bargman CI, Weinberg RA. Oncogenic activation of the neu-encoded receptor protein by point mutation and deletion. EMBO J 7:2043-2052, 1988.
11. Khun EJ, Kurnot RA, Sesterhenn IA. Expression of the c-erbB-2 HER-2/neu oncoprotein in human prostatic carcinoma. J Urol 150:1427-1433, 1993.
12. Yu D, Wang SS, Sulski KM, Tsa CM, Nicholson GL, Hung M-C. c-erbB2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties. Cancer Res 54:3260-3266, 1994.
13. Pantel K, Schlimok G, Braun S, et al. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 85:1419-1424, 1993.
14. Fox SB, Persad RA, Coleman N, Day CA, Silcocks PB, Collins CC. Prognostic value of c-erbB-2 and epidermal growth factor receptor in stage A1 (T1a) prostatic adenocarcinoma. Br J Urol 74:214-220, 1994.
15. Chang S-M, Chung LWK. Interaction between prostatic fibroblast and epithelial cells in culture: Role of androgen. Endocrinology 125:2719-2727, 1989.
16. Sikes RA, Chung LWK. Acquisition of a tumorigenic phenotype by a rat ventral prostate epithelial cell line expressing a transfected activated neu oncogene. Cancer Res 52:3174-3181, 1992.
17. Mohler JL, Partin AW, Isaacs JT, Coffey DS. Metastatic potential prediction by a visual grading system of cell motility: Prospective validation in the Dunning R-3327 prostatic adenocarcinoma model. Cancer Res 48:4312-4317, 1988.
18. Morton RA, Ewing CM, Nagafuchi A, Tsukita S, Isaacs WR. Reduction of E-cadherin levels and deletion of the α-catenin gene in human prostate cancer cells. Cancer Res 53:3585-3590, 1993.
19. Bussemakers MJG, van Moorselaar RJA, Giroldi LA, et al. Decreased expression of E-cadherin in the progression of rat prostatic cancer. Cancer Res 52:2916-2922, 1992.
20. Freeman MR, Song GY, Carson DD, Guthrie PD, Chung LWK. Extracellular matrix and androgen receptor expression associated with spontaneous transformation of rat prostate fibroblasts. Cancer Res 51:1910-1916, 1991.
21. Schalken JA, Ebeling SB, Isaacs JT, et al. Down modulation of fibronectin messenger RNA in metastasizing rat prostatic cancer cells revealed by differential hybridization analysis. Cancer Res 48:2042-2046, 1988.
22. Neomoto R, Kawamura H, Miyakawa I, et al. Immunohistochemical detection of proliferating cell nuclear antigen PCNA/cyclin in human prostate adenocarcinoma. J Urol 149:165-169, 1993.
23. Carroll PR, Waldman FM, Rosenau W, et al. Cell proliferation in prostatic adenocarcinoma: In vitro measurement by 5-bromodeoxyuridine incorporation and proliferating cell nuclear antigen expression. J Urol 149:403-407, 1993.
24. Saitoh H, Hida M, Shimbo T, et al. Metastatic patterns of prostatic cancer: Correlation between sites and number of organs involved. Cancer 54:3078-3084, 1984.
25. Naito S, von Eschenbach AC, Giavazzi R, Fidler IJ. Growth and metastasis of tumor cells isolated from a human renal cell carcinoma implanted into different organs of nude mice. Cancer Res 46:4109-4115, 1986.
26. Chung LW, Li W, Gleave ME, et al. Human prostate cancer model: Roles of growth factors and extracellular matrices. J Cell Biochem (Suppl) 16H:99-105, 1992.
27. Niehans GA, Singleton TP, Dykoski D, Kang DT. Stability of HER 2/neu expression over time and at multiple metastatic sites. J Natl Cancer Inst 85:1230-1235, 1993.
28. Harper ME, Goddard L, Wilson DW, et al. Pathological and clinical associations of Ki-67 defined growth factors in human prostatic carcinoma. Prostate 21:75-84, 1992.
29. Teixeira CR, Tanaka S, Haruma K, Yoshihara M, Sumii K, Kajiyama G. Proliferating cell nuclear antigen expression at the invasive tumor margin predicts malignant potential of colorectal carcinomas. Cancer 73:575-577, 1994.
30. Nishida T, Tanaka S, Haruma K, Yoshihara M, Sumii K, Kajiyama G. Histologic grade and cellular proliferation at the deepest invasive portion correlate with the high malignancy of submucosal invasive gastric carcinoma. Oncology 52:340-346, 1995.
31. Liotta LA. Tumor invasion and metastases - Role of the extracellular matrix: Rhoads Memorial Award Lecture. Cancer Res 46:1-7, 1986.
32. Liotta LA, Kohn EC. Molecular insights into cancer invasion: Strategies for prevention and intervention. Cancer Res 55:1856-1862, 1995.
33. Vieminckx K, Vakaet L, Mareel M, Fiers W, Van Roy F. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppresser role. Cell 66:107-119, 1991.
34. Hermiston ML, Wong MH, Gordon JI. Forced expression of E-cadherin in the mouse intestinal epithelium slows cell migration and provides evidence for nonautonomous regulation of cell fate in a self-renewing system. Genes Dev 10:985-996, 1996.
35. Hoosein NM, Boyd DD, Hollas WJ, Mazar A, Heineken J, Chung WC. Involvement of urokinase and its receptor in the invasiveness of human prostatic carcinoma cell lines. Cancer Commun 3:255-264, 1991.
36. Knox JD, Mack CF, Powell WC, Bowden GT, Nagle RB. Prostate tumor cell invasion: A comparison of orthotopic and ectopic models. Invasion Metastasis 13:325-331, 1993.
37. Shetty S, Kumar A, Johnson AR, et al. Differential expression of the urokinase receptor in fibroblasts from normal and fibrotic human lungs. Am J Respir Cell Mol Biol 1 5:78-87, 1996.
38. Southgate KM, Davies M, Booth RF, Newby AC. Involvement of extracellular matrix degrading metalloproteinases in rabbit aortic smooth-muscle cell proliferation. Biochem J 288:93-99, 1992.
39. Dedhar S. Integrins and tumor invasion. BioEssays 12:583-590, 1990.
40. Sheppard D. Epithelial integrins. BioEssays 18:655-660, 1996.
41. Van Waes C, Surh DM, Chen Z, et al. Increase in suprabasilar integrin adhesion molecule expression in human epidermal neoplasms accompanies increased proliferation occurring with immortalization and tumor progression. Cancer Res 55:5434-5444, 1995.
42. Dedhar S, Saulnier R, Nagle R, Overall CM. Specific alteration in the expression of alpha 3 beta 1 integrins in highly invasive and metastatic variants of human prostate carcinoma cells selected by in vitro invasion through reconstituted basement membrane. Clin Exp Metastasis 11:391-400, 1993.
43. Borg A, Baldetorp B, Ferno M, Killander D, Olson H, Sigurdson H. ERBB2 amplification in breast cancer with a high rate of proliferation. Oncogene 6:137-143, 1991.
44. Stocklin E, Botteri F, Groner B. An activated allele of the c-erbB-2 oncogene impairs kidney and lung function and causes early death of transgenic mice. J Cell Biol 122:199-209, 1993.
45. Colomer R, Lupu R, Bacus SS, Gelmann EP. erbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification. Br J Cancer 70:819-825, 1994.
46. Auvinen M, Paasinen A, Anderson LC, Holtta E. Ornithine decarboxylase activity is critical for cell transformation. Nature 360:355-358, 1992.
47. Lewis GD, Lofgren JA, McMurtrey AS, et al. Growth regulation of human breast and ovarian tumor cells by heregulin: Evidence for requirement of ErbB2 as a critical component in mediating heregulin responsiveness. Cancer Res 56:1457-1465, 1996.
48. erbB2, is associated with anti-proliferative activity. Oncogene 12:705-713, 1996.
49. Beerli RR, Hynes NE. Epidermal growth factor-related peptides activated distinct subsets of ErbB receptors and differ in their biological activities. J Biol Chem 271:6071-6076, 1996.
50. Karunagaran D, Tzahar E, Liu N, Wen D, Yarden Y. Neu differentiation factor inhibits EGF binding. J Biol Chem 270:9982-9990, 1995.